Page 69 - Read Online

Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50 Page 159
of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol 2011;11:862-72. DOI PubMed PMC
236. Jiao S, Subudhi SK, Aparicio A, et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to
immune checkpoint therapy. Cell 2019;179:1177-90.e13. DOI
237. Tan Y, Wang M, Zhang Y, et al. Tumor-associated macrophages: a potential target for cancer therapy. Front Oncol 2021;11:693517.
DOI PubMed PMC
238. Kumari N, Choi SH. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J Exp Clin
Cancer Res 2022;41:68. DOI PubMed PMC
239. Sleeman JP. The lymph node pre-metastatic niche. J Mol Med 2015;93:1173-84. DOI PubMed
240. Ioannidou E, Moschetta M, Shah S, et al. Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and
molecular targets. Int J Mol Sci 2021;22:9926. DOI PubMed PMC
241. Sharma V, Dong H, Kwon E, Karnes RJ. Positive pelvic lymph nodes in prostate cancer harbor immune suppressor cells to impair
tumor-reactive T cells. Eur Urol Focus 2018;4:75-9. DOI
242. Chen S, Zhu G, Yang Y, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human
prostate cancer progression. Nat Cell Biol 2021;23:87-98. DOI
243. Klusa D, Lohaus F, Furesi G, et al. Metastatic spread in prostate cancer patients influencing radiotherapy response. Front Oncol
2020;10:627379. DOI PubMed PMC
244. He ZN, Zhang CY, Zhao YW, et al. Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung
cancer. Discov Oncol 2023;14:185. DOI PubMed PMC
245. Venkatachalam S, McFarland TR, Agarwal N, Swami U. Immune checkpoint inhibitors in prostate cancer. Cancers 2021;13:2187.
DOI PubMed PMC
246. Gonzalez-Velez M, Bryce A. How to approach immune checkpoint inhibitor therapy in prostate cancer. Urol Times Urologists
Cancer Care 2020;9. Available from: https://www.urologytimes.com/view/how-to-approach-immune-checkpoint-inhibitor-therapy-
in-prostate-cancer [Last accessed on 29 Mar 2024].
247. Wong YNS, Sankey P, Josephs DH, et al. Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature
(NEPTUNES). J Clin Oncol 2019;37:tps5090. DOI
248. Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor
expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS
One 2015;10:e0130142. DOI PubMed PMC
249. Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat
Commun 2017;8:1751. DOI PubMed PMC
250. Subudhi SK, Vence L, Zhao H, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment
of patients with prostate cancer. Sci Transl Med 2020;12:eaaz3577. DOI
251. Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or
minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017;35:40-7.
DOI PubMed
252. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant
prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3
trial. Lancet Oncol 2014;15:700-12. DOI
253. Graff JN, Burgents J, Liang LW, Stenzl A. Phase III study of pembrolizumab (Pembro) plus enzalutamide (Enza) versus placebo plus
enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641. J Clin Oncol 2020;38:TPS258. DOI
254. Antonarakis ES, Park SH, Goh JC, et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected
metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial. J Clin Oncol
2023;41:3839-50. DOI PubMed PMC
255. Petrylak DP, Ratta R, Matsubara N, et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate
cancer (mCRPC): randomized, double-blind, phase 3 KEYNOTE-921 study. J Clin Oncol 2023;41:19. DOI
256. Powles T, Yuen KC, Gillessen S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant
prostate cancer: a randomized phase 3 trial. Nat Med 2022;28:144-53. DOI PubMed PMC
257. Fizazi K, González Mella P, Castellano D, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-
resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer 2022;160:61-71. DOI
258. Meng L, Yang Y, Mortazavi A, Zhang J. Emerging immunotherapy approaches for treating prostate cancer. Int J Mol Sci
2023;24:14347. DOI PubMed PMC
259. Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Ann Oncol 2018;29:1807-13. DOI
260. Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate
cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020;38:395-405. DOI
261. Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 2018;11:475-86.
DOI PubMed PMC
262. Wang S, Xie K, Liu T. Cancer immunotherapies: from efficacy to resistance mechanisms - not only checkpoint matters. Front
Immunol 2021;12:690112. DOI PubMed PMC
263. Liang H, Liu Y, Guo J, et al. Progression in immunotherapy for advanced prostate cancer. Front Oncol 2023;13:1126752. DOI
PubMed PMC